参考文献：

[1] Rosales, Francisco J., et al. "Determination of a cut-off value for the molar ratio of retinol-binding protein to transthyretin (RBP: TTR) in Bangladeshi patients with low hepatic vitamin A stores." The Journal of nutrition 132.12 (2002): 3687-3692.

[2] Wojtczak, Andrzej, Piotr Neumann, and Vivian Cody. "Structure of a new polymorphic monoclinic form of human transthyretin at 3 Å resolution reveals a mixed complex between unliganded and T4-bound tetramers of TTR." Acta Crystallographica Section D: Biological Crystallography 57.7 (2001): 957-967.

[3] Zhao, Xiaoya, et al. "Screening and Analysis of Thyroid-Disrupting Chemicals Based on Selective Recognition for a Thyroxine-Binding Peptide." Int. J. Electrochem. Sci 16.211012 (2021): 2.

[4] Norsa, Lorenzo, et al. "Night blindness in cystic fibrosis: the key role of vitamin A in the digestive system." Nutrients 11.8 (2019): 1876.

[5] Bemporad, Francesco, et al. "The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis." Pharmaceuticals 15.3 (2022): 277.

[6] Driggin, Elissa, et al. "Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype." Amyloid 27.2 (2020): 73-80.

[7] Cotrina, Ellen Y., et al. "Targeting transthyretin in Alzheimer's disease: drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease." European Journal of Medicinal Chemistry 226 (2021): 113847.

[8] Hayashi, Yuya, and Hirofumi Jono. "Recent advances in oligonucleotide-based therapy for transthyretin amyloidosis: clinical impact and future prospects." Biological and Pharmaceutical Bulletin 41.12 (2018): 1737-1744.

[9] Kapoor, Mahima, et al. "Clinical presentation, diagnosis and treatment of TTR amyloidosis." journal of neuromuscular diseases 6.2 (2019): 189-199.

[10] Azevedo, Estefania, et al. "Transthyretin-related amyloidoses: a structural and thermodynamic approach." Amyloidosis 1 (2013).

[11] Buxbaum, Joel N., and Natàlia Reixach. "Transthyretin: the servant of many masters." Cellular and molecular life sciences 66.19 (2009): 3095-3101.

[12] Monteiro, E., R. Perdigoto, and A. L. Furtado. "Liver transplantation for familial amyloid polyneuropathy. "Hepato-gastroenterology 45.23 (1998): 1375-1380.

[13] Sekijima, Yoshiki, Jeffery W. Kelly, and Shu-ichi Ikeda. "Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses." Current pharmaceutical design 14.30 (2008): 3219-3230.

[14] Liz, Márcia A., et al. "Aboard transthyretin: from transport to cleavage." IUBMB life 62.6 (2010): 429-435.

[15] Rozenbaum, Mark H., et al. "Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review." Cardiology and therapy 10.1 (2021): 141-159.

[16] Adams, David, et al. "Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy." journal of neurology 268.6 (2021): 2109-2122.

[17] Gião, Tiago, et al. "Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer's disease." International journal of molecular sciences 21.6 (2020): 2075.

[18] Ko, Emily M., et al. "The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance." Gynecologic oncology 133.1 (2014): 28-32.

[19] Lee, Chih-Chun, et al. "Transthyretin stimulates tumor growth through regulation of tumor, immune, and endothelial cells." The Journal of Immunology 202.3 (2019): 991-1002.

[20] Megerian, Cliff A., et al. "Differential expression of transthyretin in papillary tumors of the endolymphatic sac and choroid plexus." the Laryngoscope 107.2 (1997): 216-221.

[21] Rozenbaum, Mark H., et al. "Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review." Cardiology and therapy 10.1 (2021): 141-159.

[22] Lamb, Yvette N., and Emma D. Deeks. "Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. "Drugs 79.8 (2019): 863-874.

[23] Teerlink, Craig C., et al. "Analysis of high-risk pedigrees identifies 11 candidate variants for Alzheimer's disease." Alzheimer's & Dementia (2021).

[24] Westermark, Gunilla T., and Per Westermark. "Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes." Experimental diabetes research 2008 (2008).

[25] Henze, Andrea, et al. "Transthyretin predicts cardiovascular outcome in hemodialysis patients with type 2 diabetes." Diabetes Care 35.11 (2012): 2365 -2372.

[26] Chen, Jiong, et al. "Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma." journal of cancer research and clinical oncology 139.7 (2013): 1117-1127.

[27] Ding, Hongmei, et al. "Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection." biomedical reports 2.5 (2014): 765-769.

[28] Shimura, Tatsuo, et al. "Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma. "ANZ Journal of Surgery 88.12 (2018): 1328-1332.

[29] Schweigert, Florian J., and Jalid Sehouli. "Transthyretin, a biomarker for nutritional status and ovarian cancer." Cancer research 65.3 (2005): 1114- 1114.

[30] Nicklasson, J. "Transthyretin as a biomarker for nutritional status during investigation for colorectal cancer." Clinical Nutrition 37 (2018): S191- S192.